株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

原発性胆汁性胆管炎治療薬の世界市場:2019年~2023年

Global Primary Biliary Cholangitis Therapeutics Market 2019-2023

発行 TechNavio (Infiniti Research Ltd.) 商品コード 881645
出版日 ページ情報 英文 131 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.20円で換算しております。
Back to Top
原発性胆汁性胆管炎治療薬の世界市場:2019年~2023年 Global Primary Biliary Cholangitis Therapeutics Market 2019-2023
出版日: 2019年06月17日 ページ情報: 英文 131 Pages
概要

症状の認知度を高めるために、世界の原発性胆汁性胆管炎治療薬市場の様々な組織やベンダーが、啓蒙活動を実施しています。例えば、PBCers Organizationは、世界規模で症状に対する意識を高めることに焦点を当てている非営利団体です。この組織はまた、原発性胆汁性胆管炎を治療するための新規治療法の開発に関する研究への資金提供にも力を入れています。これにより、原発性胆管胆管炎治療薬の売上が拡大し、世界の原発性胆汁性胆管炎治療薬市場が予測期間中に10%近くのCAGRで拡大する見込みです。

当レポートでは、世界の原発性胆汁性胆管炎市場について調査分析し、市場規模および成長率、市場動向、市場促進要因・課題、市場機会について検証するほか、主要ベンダーなどについて、体系的な情報を提供しています。

目次

第1章 エグゼクティブサマリー

第2章 調査範囲

  • イントロダクション1
  • イントロダクション2
  • 米ドルの通貨換算レート

第3章 市場状況

  • 市場のエコシステム
  • 市場の特徴
  • 市場セグメンテーション分析

第4章 市場規模

  • 市場の定義
  • 市場規模(2018年)
  • 市場規模および予測(2018年~2023年)

第5章 ファイブフォース分析

  • バイヤーの交渉力
  • サプライヤーの交渉力
  • 新規参入の脅威
  • 代替品の脅威
  • 競争相手の脅威
  • 市況

第6章 パイプライン

第7章 市場セグメンテーション:製品別

  • 市場セグメンテーション:製品別
  • 製品別比較:市場規模および予測(2018年~2023年)
  • OCALIVA
  • ウルソジオール
  • その他
  • 市場機会:製品別

第8章 顧客情勢

第9章 地域別情勢

  • 地域別セグメンテーション
  • 地域別比較:市場規模および予測(2018年~2023年)
  • 北米
  • 欧州
  • アジア
  • その他
  • 主要国
  • 市場機会

第10章 意思決定の枠組み

第11章 成長要因と課題

  • 市場成長要因
  • 市場の課題

第12章 市場動向

  • 強力なパイプライン
  • 指定薬品の増加
  • 再生療法の登場

第13章 ベンダー情勢

  • 概要
  • 創造的破壊の状況
  • 競合シナリオ

第14章 ベンダー分析

  • 対象ベンダー
  • ベンダー分類
  • ベンダーの市場ポジショニング
  • Abbott Laboratories
  • Allergan Plc
  • Eli Lilly and Co.
  • Intercept Pharmaceuticals Inc.
  • 武田薬品工業

第15章 付録

  • 調査方法
  • 略語のリスト
  • ベンダーの市場ポジショニングの定義

第16章 TECHNAVIOについて

図表
  • Exhibit 01: Global pharmaceuticals market
  • Exhibit 02: Segments of global pharmaceuticals market
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market segments
  • Exhibit 05: Market definition - Inclusions and exclusions checklist
  • Exhibit 06: Market size 2018
  • Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 09: Five forces analysis 2018
  • Exhibit 10: Five forces analysis 2023
  • Exhibit 11: Bargaining power of buyers
  • Exhibit 12: Bargaining power of suppliers
  • Exhibit 13: Threat of new entrants
  • Exhibit 14: Threat of substitutes
  • Exhibit 15: Threat of rivalry
  • Exhibit 16: Market condition - Five forces 2018
  • Exhibit 17: Global primary biliary cholangitis therapeutics market pipeline: Overview
  • Exhibit 18: Global primary biliary cholangitis therapeutics market pipeline: Snapshot
  • Exhibit 19: Product - Market share 2018-2023 (%)
  • Exhibit 20: Comparison by product
  • Exhibit 21: OCALIVA - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 22: OCALIVA - Year-over-year growth 2019-2023 (%)
  • Exhibit 23: Ursodiol - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 24: Ursodiol - Year-over-year growth 2019-2023 (%)
  • Exhibit 25: Others - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 26: Others - Year-over-year growth 2019-2023 (%)
  • Exhibit 27: Market opportunity by product
  • Exhibit 28: Customer landscape
  • Exhibit 29: Market share by geography 2018-2023 (%)
  • Exhibit 30: Geographic comparison
  • Exhibit 31: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 32: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 33: Top 3 countries in North America
  • Exhibit 34: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 35: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 36: Top 3 countries in Europe
  • Exhibit 37: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 38: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 39: Top 3 countries in Asia
  • Exhibit 40: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 41: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 42: Top 3 countries in ROW
  • Exhibit 43: Key leading countries
  • Exhibit 44: Market opportunity
  • Exhibit 45: Impact of drivers and challenges
  • Exhibit 46: Vendor landscape
  • Exhibit 47: Landscape disruption
  • Exhibit 48: Vendors covered
  • Exhibit 49: Vendor classification
  • Exhibit 50: Market positioning of vendors
  • Exhibit 51: Abbott Laboratories - Vendor overview
  • Exhibit 52: Abbott Laboratories - Business segments
  • Exhibit 53: Abbott Laboratories - Organizational developments
  • Exhibit 54: Abbott Laboratories - Geographic focus
  • Exhibit 55: Abbott Laboratories - Segment focus
  • Exhibit 56: Abbott Laboratories - Key offerings
  • Exhibit 57: Abbott Laboratories - Key customers
  • Exhibit 58: Allergan Plc - Vendor overview
  • Exhibit 59: Allergan Plc - Business segments
  • Exhibit 60: Allergan Plc - Organizational developments
  • Exhibit 61: Allergan Plc - Geographic focus
  • Exhibit 62: Allergan Plc - Segment focus
  • Exhibit 63: Allergan Plc - Key offerings
  • Exhibit 64: Allergan Plc - Key customers
  • Exhibit 65: Eli Lilly and Co. - Vendor overview
  • Exhibit 66: Eli Lilly and Co. - Business segments
  • Exhibit 67: Eli Lilly and Co. - Organizational developments
  • Exhibit 68: Eli Lilly and Co. - Geographic focus
  • Exhibit 69: Eli Lilly and Co. - Segment focus
  • Exhibit 70: Eli Lilly and Co. - Key offerings
  • Exhibit 71: Eli Lilly and Co. - Key customers
  • Exhibit 72: Intercept Pharmaceuticals Inc. - Vendor overview
  • Exhibit 73: Intercept Pharmaceuticals Inc. - Business segments
  • Exhibit 74: Intercept Pharmaceuticals Inc. - Organizational developments
  • Exhibit 75: Intercept Pharmaceuticals Inc. - Geographic focus
  • Exhibit 76: Intercept Pharmaceuticals Inc. - Key offerings
  • Exhibit 77: Intercept Pharmaceuticals Inc. - Key customers
  • Exhibit 78: Takeda Pharmaceutical Co. Ltd. - Vendor overview
  • Exhibit 79: Takeda Pharmaceutical Co. Ltd. - Business segments
  • Exhibit 80: Takeda Pharmaceutical Co. Ltd. - Organizational developments
  • Exhibit 81: Takeda Pharmaceutical Co. Ltd. - Geographic focus
  • Exhibit 82: Takeda Pharmaceutical Co. Ltd. - Key offerings
  • Exhibit 83: Takeda Pharmaceutical Co. Ltd. - Key customers
  • Exhibit 84: Validation techniques employed for market sizing
  • Exhibit 85: Definition of market positioning of vendors
目次
Product Code: IRTNTR31508

About this market

Primary biliary cholangitis is a chronic autoimmune disease in which intrahepatic bile ducts are damaged over a period of time. Technavio's primary biliary cholangitis therapeutics market analysis considers sales of OCALIVA, ursodiol, and others. Our analysis also considers the sales of primary biliary cholangitis therapeutics in Asia, Europe, North America, ROW. In 2018, the OCALIVA segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as strong efficacy of OCALIVA to target the T-cells that are known to cause primary biliary cholangitis will play a significant role in the OCALIVA segment to maintain its market position. Also, our global primary biliary cholangitis therapeutics market report looks at factors such as increasing collaborations, growing risk factors, and rising awareness campaigns to reduce further complications. However, asymptomatic nature of the disease, lack of approved therapies, and availability of alternative therapies may hamper the growth of the primary biliary cholangitis therapeutics industry over the forecast period.

Overview

Growing awareness campaigns to reduce further complications

To increase the awareness of the indication, various organizations and the vendors in the global primary biliary cholangitis therapeutics market are conducting awareness campaigns. For instance, the PBCers Organization is a non-profit organization that focuses on increasing the awareness of the indication globally. The organization also focuses on funding the research on the development of novel therapies to treat primary biliary cholangitis. This will boost the sales of primary biliary cholangitis therapeutics and lead to the expansion of the global primary biliary cholangitis therapeutics market at a CAGR of close to 10% during the forecast period.

Advent of regenerative therapy

Research on regenerative therapy is gaining traction as the liver transplant method of treatment causes post-surgery complications to patients. Also, at present, there is no cure for the indication other than liver transplant due to the recurring nature of the disease. This is encouraging researchers to conduct study on stem cell transplantation, which can replace destroyed cells in the bile duct. This ongoing research is expected to have a positive impact on the overall market growth.

For the detailed list of factors that will drive the global primary biliary cholangitis therapeutics market during the forecast period 2019-2023, view our report.

Competitive Landscape

With the presence of few major players, the global primary biliary cholangitis therapeutics market is concentrated. Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading primary biliary cholangitis therapeutics manufacturers, that include Abbott Laboratories, Allergan Plc, Eli Lilly and Co., Intercept Pharmaceuticals Inc., and Takeda Pharmaceutical Co. Ltd.

Also, the primary biliary cholangitis therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: PIPELINE

PART 07: MARKET SEGMENTATION BY PRODUCT

  • Market segmentation by product
  • Comparison by product
  • OCALIVA - Market size and forecast 2018-2023
  • Ursodiol - Market size and forecast 2018-2023
  • Others - Market size and forecast 2018-2023
  • Market opportunity by product

PART 08: CUSTOMER LANDSCAPE

PART 09: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 12: MARKET TRENDS

  • Strong pipeline
  • Increasing drug designations
  • Advent of regenerative therapy

PART 13: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 14: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Abbott Laboratories
  • Allergan Plc
  • Eli Lilly and Co.
  • Intercept Pharmaceuticals Inc.
  • Takeda Pharmaceutical Co. Ltd.

PART 15: APPENDIX

  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors

PART 16: EXPLORE TECHNAVIO

Back to Top